

INDEX OF CONTENTS	I
INDEX OF CONTENTS	I
LIST OF FIGURES	VI
LIST OF TABLES	VIII
LIST OF ABBREVIATIONS	IX
ABSTRACT	XI
ZUSAMMENFASSUNG	XII

Index of Contents

1 INTRODUCTION	1
1.1 CHALLENGES TO AN AGEING SOCIETY	1
1.2 PARKINSON'S DISEASE	1
1.3 PARKINSON ETIOLOGY: GLOBAL AND CELL SPECIFIC FACTORS	3
1.3.1 PAN-CELLULAR FACTORS	3
1.3.2 CELL-SPECIFIC FACTORS	4
1.4 MITOCHONDRIA: THE CENTRAL FACTOR IN PARKINSON'S DISEASE?	8
1.5 MITOCHONDRIA	9
1.5.1 THE MITOCHONDRIAL GENOME	12
1.5.2 MITOCHONDRIAL DNA REPLICATION	13
1.5.3 TWO DIVERGING MODELS OF MTDNA REPLICATION	16
1.5.4 MITOCHONDRIAL DNA MUTATIONS	17
1.5.5 HOW ARE MTDNA DELETIONS GENERATED?	18
1.6 AIM OF THE STUDY	20
2 MATERIAL AND METHODS	21
2.1 CHEMICALS	21
2.1.1 CELL CULTURE CHEMICALS	22
2.1.2 ENZYMES	22
2.1.3 KITS & ASSAYS	23
2.1.4 BUFFERS AND SOLUTIONS	24
2.2 CELL BIOLOGY	26
2.2.1 THE SH-SY5Y CELL LINE	26
2.2.2 SH-SY5Y CULTURE AND DIFFERENTIATION	26

2.2.3	CELL COUNTING	26
2.2.4	PROLIFERATION/DIFFERENTIATION TESTS: MTT AND XTT	27
2.2.4.1	MTT assay for proliferating cells	27
2.2.4.2	XTT assay for differentiated cells	27
2.2.5	SH-SY5Y CLONE GENERATION	28
2.2.6	FURTHER CLONE SELECTION (PHENOTYPING)	28
2.2.7	MITOTRACKER RED & PICOGREEN STAINING	28
2.2.8	ISOLATION OF MITOCHONDRIA	29
2.3	DNA BASED METHODS	29
2.3.1	DNA ISOLATION USING COMMERCIALY AVAILABLE KITS	29
2.3.2	PHENOL-CHLOROFORM DNA EXTRACTION	29
2.3.3	PHENOL-FREE mtDNA EXTRACTION	30
2.3.4	DNA/RNA QUALITY AND QUANTITY CONTROL	30
2.3.5	AGAROSE GEL ELECTROPHORESIS	30
2.3.6	DNA ELUTION FROM GELS	31
2.3.7	RESTRICTION DIGESTS	31
2.3.8	PURIFICATION OF RESTRICTED PCR PRODUCTS	31
2.3.9	PROTOCOL FOR BLUNTING DNA	31
2.3.10	LIGATION	31
2.3.11	<i>IN VITRO</i> SITE-DIRECTED MUTAGENESIS	32
2.3.12	DNA PRECIPITATION	32
2.4	PCR APPLICATIONS	33
2.4.1	STANDARD PCR	33
2.4.2	MTDNA DELETION DETECTION STRATEGY IN MOUSE	34
2.4.2.1	Initial screening for deletions in mouse mtDNA	34
2.4.2.2	Quantitative PCR (qPCR): mtDNA deletion quantitation	35
2.4.3	DETERMINATION OF MTDNA COPY NUMBER	37
2.4.4	MTDNA DELETION SCREEN: SINGLE CELL PCR (NESTED)	37
2.4.5	LONG-RANGE PCR	38
2.4.6	MTDNA DELETION DETECTION STRATEGY IN HUMAN SH-SY5Y CELLS	39
2.4.6.1	Nested PCR	39
2.4.6.2	Two-step long-range PCR: nested amplification of major arc	40
2.4.7	CLONING OF PCR PRODUCTS	40
2.4.8	COLONY PCR	40
2.4.9	SOUTHERN BLOT: ANALYSES OF MTDNA TOPOLOGY	40
2.4.10	DNA SEQUENCING	41

2.5 RNA BASED METHODS	42
2.5.1 RNA ISOLATION	42
2.5.2 RT: REVERSE TRANSCRIPTION	42
2.5.2.1 RT-PCR	42
2.5.3 SINGLE CELL RT: REVERSE TRANSCRIPTION	42
2.5.3.1 Single cell RT-PCR	43
2.6 PROTEIN BASED METHODS	43
2.6.1 CRUDE CELL-LYSATES	43
2.6.2 MONOAMINE OXIDASE ASSAY	43
2.7 HISTOLOGY	44
2.7.1 STAINING FOR TYROSINE HYDROXYLASE: IMMUNOFLUORESCENCE	44
2.7.2 STAINING FOR CELLULAR INTEGRITY: H&E	44
2.7.3 STAINING FOR COLLAGEN FIBROSIS: Picro-sirius red staining	44
2.7.4 STAINING FOR MITOCHONDRIAL DYSFUNCTION: COX/SDH staining	44
2.8 MOUSE HANDLING	45
2.9 STATISTICAL ANALYSES	45
2.10 CONSTRUCTED VECTORS	45
3 RESULTS	49
3.1 MTDNA DELETIONS <i>IN VIVO</i>: MOUSE BRAIN AND ADRENAL GLAND	49
3.1.1 INITIAL PCR SCREEN TO DETECT MTDNA DELETIONS	49
3.1.2 ESTABLISHING qPCR PROTOCOLS TO QUANTITATE MTDNA DELETIONS	51
3.1.3 MTDNA DELETIONS IN MOUSE BRAIN TISSUES	53
3.1.4 MTDNA DELETIONS IN MOUSE ADRENAL GLAND	56
3.1.5 TISSUE SPECIFIC MTDNA DELETION PATTERNS	56
3.2 MAO OVEREXPRESSION IN ASTROCYTES LEADS TO INCREASED MTDNA DELETIONS IN S. NIGRA	57
3.3 MTDNA COPY NUMBERS IN MOUSE BRAIN AND ADRENAL GLAND	58
3.4 SH-SY5Y AS AN <i>IN VITRO</i> MODEL FOR DOPAMINERGIC CELLS	60
3.5 CYTOTOXICITY OF DOPAMINE METABOLITES IN SH-SY5Y CELLS	62
3.6 CHARACTERISATION OF STABLE SH-SY5Y CLONES	64
3.6.1 GENOTYPING AND PHENOTYPIC SCREENING	64
3.6.2 ENZYME OVEREXPRESSION IN GENERATED SH-SY5Y CLONES	66
3.7 MTDNA DELETIONS <i>IN VITRO</i>: SH-SY5Y NEUROBLASTOMA CELLS	67
3.7.1 MAJOR ARC MTDNA DELETION SCREENING WITH LONG-RANGE PCR	68
3.7.2 VALIDATING NOVEL NESTED PCR PROTOCOL TO DETECT MTDNA DELETIONS	68
3.7.3 NESTED PCR MTDNA DELETION SCREENING IN SH-SY5Y NEUROBLASTOMA CELLS	69

3.7.4	MTDNA DELETIONS IN SH-SY5Y NEUROBLASTOMA CELLS: PROLIFERATION VERSUS DIFFERENTIATION	69
3.7.5	CONFIRMATION OF MULTIPLE MTDNA DELETIONS IN SH-SY5Y NEUROBLASTOMA CELLS	71
3.7.6	MTDNA DELETIONS IN SH-SY5Y NEUROBLASTOMA CELLS TREATED WITH DOPAMINE	73
3.7.7	MTDNA DELETIONS IN SH-SY5Y NEUROBLASTOMA CELLS TREATED WITH MPP ⁺ AND TYROSINE	74
3.7.8	MTDNA DELETIONS IN OVEREXPRESSING SH-SY5Y NEUROBLASTOMA CELLS TREATED WITH SPECIFIC INHIBITORS	76
3.8	MECHANISM OF MTDNA DELETION GENERATION	77
3.9	MTDNA COPY NUMBERS IN SH-SY5Y NEUROBLASTOMA CELLS UPON DIFFERENTIATION	79
3.10	MTDNA DELETION SCREENING IN SINGLE CELLS OF MOUSE MIDBRAIN	80
3.11	CHARACTERISATION OF THE MITOCHONDRIAL DYSFUNCTION IN THE CATECHOLAMINERGIC ADRENAL MEDULLA	81
4	<u>DISCUSSION</u>	85
4.1	NOVEL PCR STRATEGIES PROVIDE SUPERIOR TOOLS TO MONITOR THE ACCUMULATION OF MTDNA DELETIONS <i>IN VIVO</i> AND <i>IN VITRO</i>	85
4.2	MITOCHONDRIAL DNA DELETIONS PREFERENTIALLY ACCUMULATE IN DOPAMINERGIC BRAIN AREAS IN MOUSE	88
4.3	OVEREXPRESSION OF DOPAMINE DEGRADING MONOAMINE OXIDASE B IN ASTROCYTES INCREASES MTDNA DELETIONS RATIOS	90
4.4	NEUROMELANIN IS NOT THE DRIVING FORCE BEHIND MTDNA DELETION ACCUMULATION IN S. NIGRA	90
4.5	MTDNA COPY NUMBERS DECREASE IN S. NIGRA AND STRIATUM WITH AGEING	91
4.6	DOPAMINE INDUCES MTDNA DELETIONS <i>IN VITRO</i>	92
4.6.1	TERMINALLY DIFFERENTIATED SH-SY5Y CELLS ACCUMULATE MTDNA DELETIONS	93
4.6.2	DOPAMINE INDUCES MTDNA DELETIONS IN DIFFERENTIATED SH-SY5Y	95
4.7	WHAT LIES BENEATH THE SELECTIVE VULNERABILITY OF DOPAMINERGIC MIDBRAIN NEURONS?	97
5	<u>CONCLUSIONS AND PERSPECTIVES</u>	99
6	<u>REFERENCES</u>	101

7	ANNEXE	113
7.1	PRIMER SEQUENCES	113
7.2	DNA LADDERS	117
7.3	VECTOR MAPS	118
7.4	COMPLETE FITTING DATA SET (FIGURE 3.1-9)	121
7.5	NESTED PCR: SEQUENCED MTDNA DELETION BREAKPOINTS	123